Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 1580 Records) |
Query Trace: Brca[original query] |
---|
Germline BRCA2 Pathogenic Variant in Primary Breast Cancer of a Down Syndrome Individual. The American journal of case reports 2023 12 24 e942208. Tsuyoshi Shinohara, Takuo Asoda, Yuta Nakano, Hiroyuki Yamada, Yoshiro Fujimo |
Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer. In vivo (Athens, Greece) 2023 12 38 (1): 467-473. Soo Hyun Oh, Soo Jin Park, Seungmee Lee, Seungho Lee, Hee Seung K |
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 12 JCO2301868. Jaleh Fallah, Jianjin Xu, Chana Weinstock, Michael H Brave, Erik Bloomquist, Mallorie H Fiero, Timothy Schaefer, Anand Pathak, Abdelrahmman Abukhdeir, Vishal Bhatnagar, Haw-Jyh Chiu, Tiffany Ricks, Christy John, Salaheldin Hamed, Christal Lee, William F Pierce, Shyam Kalavar, Reena Philip, Shenghui Tang, Laleh Amiri-Kordestani, Richard Pazdur, Paul G Kluetz, Daniel Suzm |
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network. Aging 2023 12 15 . Hongyan Qian, Rui Ji, Cheng Shen, Yinze Wei, Chenyi Sheng, Qichao Ni, Jing Pan, Yifan Chi, Huan You, Ying Miao, Minxin Shi, Xianghua Huang, Aiguo Sh |
Cerebellar metastasis of ovarian cancer: a case report. Journal of medical case reports 2023 12 17 (1): 553. Eleonora Cabitza, Marta Pirola, Cinzia Baldessari, Giuditta Bernardelli, Elena Zunarelli, Stefania Pipitone, Maria Giuseppa Vitale, Cecilia Nasso, Eleonora Molinaro, Marco Oltrecolli, Elisa D'Agostino, Vincenzo Dario Mandato, Andrea Palicelli, Massimo Dominici, Roberto Sabbati |
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 2023 12 . Judith Balmaña, Peter A Fasching, Fergus J Couch, Suzette Delaloge, Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Gonçalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, Antonio Antón-Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, |
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer. Gynecologic oncology 2023 12 181 33-39. Ji Hyun Kim, Se Ik Kim, Eun Young Park, Eun Taeg Kim, Hyesu Kim, Sangeon Kim, Sang-Yoon Park, Myong Cheol L |
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer 2023 12 . Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, Denái R Milton, Angelica M Gutierrez, Stephen K Gruschkus, John E Lewis, Rashmi K Murthy, Banu K Ar |
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden. PharmacoEconomics - open 2023 12 . Maria Polyzoi, Mattias Ekman, Anja Reithmeier, Johanna Jacob, Emma Karlsson, Evelina Bertranou, Barbro Linderholm, Robert Hett |
Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer. Clinical case reports 2024 4 12 (4): e8680. Xia-Bo Shen, Jia-Yi Wu, Jia-Ying Li, Xi-Ying Shao, Xiao-Jia Wa |
Variants in BRCA1/2 in a hospital-based cohort in Chile and national literature review. Ecancermedicalscience 2024 4 18 1683. Fernanda J Martin, Isabel M Saffie, Mabel A Hurtado, Diana Avila-Jaque, Rodrigo A Lagos, Carolina A Selman, Jonathan Z Huserman, Valentina A Castillo, Badir J Chahu |
Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area. BMC cancer 2024 4 24 (1): 411. Zhiyuan Wu, Qingyun Zhang, Yiting Jin, Xinju Zhang, Yanli Chen, Can Yang, Xuemei Tang, Haowen Jiang, Xiaoyi Wang, Xinli Zhou, Feng Yu, Bing Wang, Ming Gu |
Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants. JAMA network open 2024 4 7 (4): e247421. Zhenzhen Zhang, Shangyuan Ye, Sarah M Bernhardt, Heidi D Nelson, Ellen M Velie, Virginia F Borges, Emma R Woodward, D Gareth R Evans, Pepper J Sched |
A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants. Clinical laboratory 2024 4 70 (4): . Jin Ju Kim, Dong Ja Kim, Eon Jeong Nam, Kyung Eun Song, Ji Yeon Ham, Yu Kyung Kim, Nan Young L |
Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Cancer pathogenesis and therapy 2024 4 2 (2): 81-90. Mingqiang Shi, Zhoujuan Li, Guoshuang Shen, Tianzhuo Wang, Jinming Li, Miaozhou Wang, Zhen Liu, Fuxing Zhao, Dengfeng Ren, Jiuda Zh |
Identification and validation of Golgi apparatus-related signature for predicting prognosis and immunotherapy response in breast cancer. Journal of cancer research and clinical oncology 2024 2 150 (2): 61. Xin Chen, Pengting Tang, Ying Kong, Deqin Chen, Kejun Ta |
Risk factors for ovarian cancer by BRCA status: a collaborative case-only analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2024 2 . Kate Gersekowski, Renhua Na, Kathryn Alsop, Rachel Delahunty, Ellen L Goode, Julie M Cunningham, Stacey J Winham, Paul D P Pharoah, Honglin Song, Penelope M We |
Genetic contribution of breast cancer genes in women of black African origin. Frontiers in genetics 2024 1 14 1302645. Rokhaya Ndiaye, Jean Pascal Demba Diop, Ahmadou Dem, Alioune Die |
Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer. Clinical Medicine Insights. Oncology 2024 1 18 11795549231219239. Yanping Li, Wenfei Du, Rui Yang, Xiaonan Wei, Haibin Li, Xiaoyuan Zha |
Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials. American journal of translational research 2024 1 15 (12): 6675-6689. Chao Li, Siyi Qiao, Min Kang, Xiaofeng Gao, Zhiru |
A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations. Diagnostic pathology 2024 1 19 (1): 9. Anne Vogel, Anna Haupts, Michael Kloth, Wilfried Roth, Nils Hartma |
BRCA 1/2 mutations and risk of uterine cancer: a systematic review and meta-analysis. BMC genomic data 2024 1 25 (1): 13. Faezeh Zakerinasab, Qumars Behfar, Reza Parsaee, Reza Hossein Zadeh, Elaheh Foroughi, Amirhesam Amirbeik, Ghazalehsadat Ahma |
Outcomes of BRCA pre-implantation genetic testing according to the parental mutation origin: a cohort study. Reproductive biology and endocrinology : RB&E 2024 1 22 (1): 8. Ilana Weizel, Tal Shavit, Yulia Shuli, Chana Adler Lazarovich, Rivka Halevi, Tal Ben Ari, Shira Yaacobi-Artzi, Yaakov Bentov, Baruch Feldman, Anat Hershko Kleme |
BRCA mutation status and pathological characterization of breast cancer in Zhoushan Islands, China. The Journal of international medical research 2024 1 52 (1): 3000605231223426. Shuhui Bao, Nini Sun, Yaling Li, Jiaojie Shu, Jing Xu, Yong Zhang, Xia Q |
A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China. Frontiers in oncology 2024 1 13 1300199. Jinghong Chen, Mengpei Zhang, Kemin Li, Yuanqiong Duan, Xiaojuan Lin, Lan Zhong, Qintong Li, Rutie Y |
Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study. Breast cancer research : BCR 2024 1 26 (1): 14. Eunhye Kang, Ji-Jung Jung, Changjin Lim, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Hyeong-Gon Mo |
BRCA mutation patients: are there other predisposing factors for ovarian cancer occurrence? A multicentre retrospective study. Gynecologic and obstetric investigation 2024 1 . Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Corm |
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 1 . Tira J Tan, Sarah Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A Traina, Carey Anders, Joe Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca De |
Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer. International journal of general medicine 2024 1 17 75-84. Yu Luo, Ru Pan, Hui Rao, Xing Chen, Haikun Ya |
Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients. Folia biologica 2024 1 69 (3): 91-98. So?a Argalácsová, ?udmila K?ížová, Martin Mat?j?, Dominika Svobodová, Michal Vo? |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: